MarketCapExport financials
Applied DNA Sciences (APDN)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Applied DNA Sciences Balance Sheet 2026-2009 | APDN
Brief balance sheet overview of Applied DNA Sciences
This overview follows the five latest available annual observations between 2021 and 2025.
Across five reporting periods, assets decreased -69.2%, from $14.4 million to $4.4 million, producing a negative trend.
Asset growth of -69.2% came with a -24.5% rise in liabilities. Financial leverage became more prominent.
The equity ratio reached 51.9% from 77.1%. A high capital share reduces dependence on liabilities.
Cash equals 37.6% of the balance sheet, compared with 45.5% five periods ago. This is the readily available cushion.
The balance sheet carries negative retained earnings of -$379.2 million. The figure may result from accumulated losses or an active capital return policy.
Balance sheet takeaway
Taken together, Applied DNA Sciences's balance sheet indicators point to elevated risk. Asset growth does not offset weak funding sources.
Annual Balance Sheet Applied DNA Sciences
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | -5.11 M | -5.91 M | - | - | -5.44 M | 986 K | -72.9 K | -2.96 M | -4.48 M | -7.31 M | 407 K | -6.36 M | -725 K | 984 K | - | - |
Long Term Debt |
- | - | 193 K | 739 K | - | - | 517 K | 1.55 M | 1.59 M | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
- | 193 K | 546 K | 499 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 1.37 M | 2.17 M | 2.06 M | - | 1.12 M | 320 K | 1.1 M | 2.64 M | - | - | - | - |
Total Current Liabilities |
1.47 M | 2.46 M | 2.4 M | 2.85 M | 4.19 M | 3.27 M | 4.27 M | 2.25 M | 2.82 M | 1.3 M | 4.08 M | 2.67 M | 3.88 M | 1.12 M | 592 K | 4.5 M | 2.79 M | - |
Total Liabilities |
1.5 M | 2.5 M | 3.82 M | 8.78 M | 9.36 M | 3.3 M | 5.63 M | 4.41 M | 4.88 M | 1.3 M | 5.2 M | 2.99 M | 4.97 M | 3.76 M | 592 K | 4.5 M | - | - |
Deferred Revenue |
3.77 K | 12.3 K | 58.8 K | 76.4 K | 564 K | 281 K | 511 K | 629 K | 1.86 M | 352 K | 1.84 M | 282 K | 583 K | 149 K | - | - | - | - |
Retained Earnings |
-404 M | -379 M | -310 M | -302 M | -293 M | -284 M | -270 M | -257 M | -248 M | -237 M | -224 M | -212 M | -200 M | -187 M | -169 M | -162 M | -151 M | - |
Total Assets |
13.6 M | 4.44 M | 12.8 M | 13.7 M | 22.3 M | 14.4 M | 11.3 M | 3.56 M | 5.63 M | 8.15 M | 15.6 M | 15.6 M | 3.51 M | 8.37 M | 1.35 M | 3.5 M | 1.41 M | - |
Cash and Cash Equivalents |
949 K | 1.67 M | 5.85 M | 7.15 M | 15.2 M | 6.55 M | 7.79 M | 559 K | 1.66 M | 2.96 M | 4.48 M | 7.31 M | 1.39 M | 6.36 M | 725 K | 2.75 M | 17.6 K | 213 K |
Book Value |
12.1 M | 1.94 M | 8.97 M | 4.87 M | 12.9 M | 11.1 M | 5.71 M | -848 K | 755 K | 6.86 M | 10.4 M | 12.6 M | -1.47 M | 4.62 M | 757 K | -995 K | 1.41 M | - |
Total Shareholders Equity |
12.5 M | 2.3 M | 9.14 M | 4.95 M | 12.9 M | 11.1 M | 5.72 M | -841 K | 755 K | 6.86 M | 10.4 M | 12.6 M | -1.47 M | 4.62 M | 757 K | -995 K | -1.6 M | -1.75 M |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Applied DNA Sciences
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | - | 48.9 K | 193 K | 334 K | - | 607 K | 739 K | 868 K | 994 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 320 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
2.5 M | 1.5 M | 2.24 M | 2.24 M | 2.5 M | 2.95 M | 2.81 M | 3.42 M | 3.82 M | 4.46 M | - | 5.78 M | 8.78 M | 8.6 M | 9.21 M | 11.1 M | 9.36 M | 5.13 M | 6.23 M | 3.01 M | 3.3 M | 1.61 M | 3.3 M | 3.95 M | 5.63 M | 5.63 M | 5.63 M | 3.65 M | 4.41 M | 4.41 M | 4.41 M | 5.38 M | 4.88 M | 4.88 M | 4.88 M | 1.47 M | 1.3 M | 1.3 M | 1.3 M | 4.59 M | 5.2 M | 5.2 M | 5.2 M | 2.49 M | 2.99 M | 2.99 M | 2.99 M | 1.72 M | 4.97 M | 4.97 M | 4.97 M | 4.36 M | 3.76 M | 3.76 M | 4.36 M | - | 592 K | - | - | - | - | - | - |
Deferred Revenue |
12.3 K | 3.77 K | 16 K | 16 K | 12.3 K | 12.3 K | 12.3 K | 217 K | 58.8 K | 51.3 K | - | 54 K | 76.4 K | 276 K | 283 K | 274 K | 564 K | 757 K | 394 K | 458 K | 281 K | 253 K | 281 K | 365 K | 511 K | 511 K | 511 K | 455 K | 629 K | 803 K | 1.21 M | 1.38 M | 1.86 M | 1.86 M | 1.86 M | 343 K | 352 K | 352 K | 352 K | 1.79 M | 1.84 M | 1.84 M | 1.84 M | 57.5 K | 282 K | 282 K | 282 K | 524 K | 583 K | 583 K | 583 K | 325 K | 149 K | 149 K | 325 K | - | - | 25 K | - | - | - | - | - |
Retained Earnings |
-379 M | -404 M | -398 M | -398 M | -379 M | -374 M | -354 M | -327 M | -310 M | -306 M | - | -304 M | -302 M | -299 M | -296 M | -296 M | -293 M | -292 M | -291 M | -289 M | -284 M | -280 M | -284 M | -275 M | -270 M | -270 M | -270 M | -259 M | -257 M | -257 M | -257 M | -251 M | -248 M | -248 M | -248 M | -240 M | -237 M | -237 M | -237 M | -228 M | -224 M | -224 M | -224 M | -215 M | -212 M | -212 M | -212 M | -208 M | -200 M | -200 M | -200 M | -193 M | -187 M | -187 M | -193 M | -178 M | -169 M | -169 M | -169 M | -164 M | -162 M | -162 M | -162 M |
Total Assets |
4.44 M | 13.6 M | 20.7 M | 20.7 M | 4.44 M | 9.93 M | 13 M | 16 M | 12.8 M | 16.7 M | - | 9.91 M | 13.7 M | 15.8 M | 19.2 M | 20.3 M | 22.3 M | 11.9 M | 13.9 M | 11.4 M | 14.4 M | 17.2 M | 14.4 M | 9.68 M | 11.3 M | 11.3 M | 11.3 M | 10.9 M | 3.56 M | 3.56 M | 3.56 M | 6.15 M | 5.63 M | 5.63 M | 5.63 M | 9.61 M | 8.15 M | 8.15 M | 8.15 M | 16.8 M | 15.6 M | 15.6 M | 15.6 M | 20.5 M | 15.6 M | 15.6 M | 15.6 M | 5.02 M | 3.51 M | 3.51 M | 3.51 M | 6.24 M | 8.37 M | 8.37 M | 6.24 M | 1.62 M | 1.35 M | 1.35 M | 1.35 M | 2.52 M | 3.5 M | 3.5 M | 3.5 M |
Cash and Cash Equivalents |
5.48 M | 949 K | 2.45 M | 2.45 M | 1.67 M | 4.73 M | 6.82 M | 9.91 M | 5.85 M | 10.7 M | 3.9 M | 4.11 M | 7.15 M | 11.5 M | 12.3 M | 12.9 M | 15.2 M | 4.68 M | 6.51 M | 2.75 M | 6.55 M | 12.2 M | 6.55 M | 4.24 M | 7.79 M | 7.79 M | 7.79 M | 8.66 M | 559 K | 559 K | 559 K | 3.14 M | 1.66 M | 1.66 M | 1.66 M | 4.76 M | 2.96 M | 2.96 M | 4.76 M | 6.7 M | 4.48 M | 4.48 M | 6.7 M | 12.4 M | 7.31 M | 7.31 M | 12.4 M | 2.87 M | 1.39 M | 1.39 M | 2.87 M | 4.2 M | 6.36 M | 6.36 M | 4.2 M | 984 K | 725 K | 725 K | 984 K | 1.94 M | 2.75 M | 2.75 M | 1.94 M |
Book Value |
1.94 M | 12.1 M | 18.5 M | 18.5 M | 1.94 M | 6.99 M | 10.2 M | 12.5 M | 8.97 M | 12.2 M | - | 4.13 M | 4.87 M | 7.19 M | 9.97 M | 9.16 M | 12.9 M | 6.79 M | 7.65 M | 8.39 M | 11.1 M | 15.6 M | 11.1 M | 5.72 M | 5.71 M | 5.71 M | 5.71 M | 7.22 M | -848 K | -848 K | -848 K | 766 K | 755 K | 755 K | 755 K | 8.14 M | 6.86 M | 6.86 M | 6.86 M | 12.2 M | 10.4 M | 10.4 M | 10.4 M | 18 M | 12.6 M | 12.6 M | 12.6 M | 3.3 M | -1.47 M | -1.47 M | -1.47 M | 1.88 M | 4.62 M | 4.62 M | 1.88 M | 1.62 M | 757 K | 1.35 M | 1.35 M | 2.52 M | 3.5 M | 3.5 M | 3.5 M |
Total Shareholders Equity |
8.97 M | 12.5 M | 18.8 M | 18.8 M | 2.3 M | 7.26 M | 10.5 M | 12.5 M | 9.14 M | 12.2 M | -175 K | 4.13 M | 4.95 M | 7.19 M | 9.97 M | 9.16 M | 12.9 M | 6.79 M | 7.65 M | 8.39 M | 11.1 M | 15.6 M | 18.6 M | 5.72 M | 5.72 M | 5.72 M | 5.72 M | 7.23 M | -841 K | -841 K | -841 K | 766 K | 755 K | 766 K | 766 K | 8.14 M | 6.86 M | 6.86 M | 8.14 M | 12.2 M | 10.4 M | 10.4 M | 10.4 M | 18 M | 12.6 M | 12.6 M | 12.6 M | 3.3 M | -1.47 M | -1.47 M | -1.47 M | 1.88 M | 4.62 M | 4.62 M | 1.88 M | -6.7 M | 757 K | 757 K | 757 K | -1.35 M | -995 K | -995 K | -995 K |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Applied DNA Sciences, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Security protection
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
VerifyMe
VRME
|
$ 7.48 | 10.32 % | $ 94.4 M |  USA |
 |
Allegion plc
ALLE
|
$ 189.55 | -0.51 % | $ 16.3 B | USA |
 |
SuperCom Ltd.
SPCB
|
$ 8.56 | 0.33 % | $ 39 M |  Israel |
 |
Verra Mobility Corporation
VRRM
|
$ 2.06 | -3.52 % | $ 328 M | USA |
 |
Vivint Smart Home
VVNT
|
- | -0.04 % | $ 2.58 B | USA |
 |
Mistras Group
MG
|
$ 20.18 | 0.1 % | $ 634 M | USA |
 |
Universal Security Instruments
UUU
|
$ 5.29 | 3.73 % | $ 12.7 M | USA |
 |
CompX International
CIX
|
$ 44.43 | 9.42 % | $ 547 M | USA |
 |
The Brink's Company
BCO
|
$ 117.4 | 2.47 % | $ 4.95 B | USA |
 |
Arlo Technologies
ARLO
|
$ 12.26 | 0.95 % | $ 1.28 B | USA |
 |
Brady Corporation
BRC
|
$ 80.02 | 0.13 % | $ 3.78 B | USA |
 |
BIO-key International
BKYI
|
$ 2.37 | -0.84 % | $ 1.58 M | USA |
 |
ADT
ADT
|
$ 9.9 | -0.35 % | $ 7.23 B | USA |
 |
MSA Safety Incorporated
MSA
|
$ 174.56 | 0.86 % | $ 6.85 B | USA |
 |
NL Industries
NL
|
$ 7.15 | -2.32 % | $ 349 M | USA |
 |
Rekor Systems
REKR
|
$ 0.33 | -6.78 % | $ 39.5 M | USA |
 |
Napco Security Technologies
NSSC
|
$ 31.37 | -0.19 % | $ 1.12 B | USA |
 |
Resideo Technologies
REZI
|
$ 19.47 | -2.92 % | $ 2.9 B | USA |
 |
Nxt-ID, Inc.
NXTD
|
- | -7.64 % | $ 22.6 M | USA |
 |
Digital Ally
DGLY
|
- | - | $ 3.09 M | USA |